Bluenote Partners With CMIC to Scale Agentic AI Across Global Clinical Development

New updates have been reported about Bluenote.

Bluenote has secured a strategic partnership with CMIC Co., Ltd., one of Japan’s largest contract research organizations, to embed its agentic AI platform across CMIC’s end‑to‑end clinical development workflows. The deal positions Bluenote’s technology at the core of CMIC’s global service offering to pharmaceutical and emerging biopharma sponsors, targeting up to a 75% reduction in cycle times for select regulatory and clinical documentation processes.

Under the agreement, CMIC will use Bluenote’s AI agents to generate and manage key documents across the development lifecycle, including protocols, statistical analysis plans, clinical study reports, eCTD modules and CMC documentation, all aligned with ICH, FDA, PMDA and EMA standards. Bluenote’s platform emphasizes full traceability to source data, validation guardrails and automated quality checks, supporting CMIC’s strategy to evolve from a traditional CRO into a technology‑driven development partner and expanding Bluenote’s footprint among major life sciences and CRO clients globally.